<DOC>
	<DOCNO>NCT01316835</DOCNO>
	<brief_summary>This study evaluate whether addition sitagliptin treatment provide additional decrease HbA1C level increase goal attainment patient inadequate glycemic control current oral anti-glycemic therapy real world practice .</brief_summary>
	<brief_title>Effectiveness Sitagliptin Glycemic Control Real World</brief_title>
	<detailed_description>To explore change glycemic control ( HbA1c FPG ) 24 week Sitagliptin treatment Type 2 Diabetic patient start Sitagliptin add therapy index period receive Sitagliptin continuously* least 24 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . All subject diagnose type 2 diabetes ( ICD9 code= 250.0 ; 250.1 ; 250.2 ; 250.3 ; 250.4 ; 250.5 ; 250.6 ) follow regularly study center start receive Sitagliptin addon treatment prior regimen index period 2 . Subjects must stable dose antidiabetic regimen , stable dose define `` least 3 month therapy/dose change '' prior add sitagliptin 3 . Subjects whose medical record minimum core data set find . 4 . Outpatient 1 . Subjects type 1 DM 2 . Subjects treat insulin regularly 3 . Subject DM result general disease , e.g . surgery , pharmaceutical product , malnutrition , infection condition 4 . Subjects participate clinical trial clinical study index period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>retrospective , sitagliptin , glycemia control , real world</keyword>
</DOC>